Contact Us
Drug Search Results
More Filters [+]

LB-100

Alternative Names: lb-100, lb100, lb 100
Latest Update: 2024-11-09
Latest Update Note: Clinical Trial Update

Product Description

Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired.

Mechanisms of Action: WEE1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: LIXTE
Company Location: EAST SETAUKET NY 11733
Company CEO: John S. Kovach
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LB-100

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Fibrosarcoma|Leiomyosarcoma|Liposarcoma, Myxoid|Myelodysplastic Syndrome|Preleukemia|Synovial Sarcoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ENHANCER

P2

Active, not recruiting

Leiomyosarcoma|Fibrosarcoma|Synovial Sarcoma|Liposarcoma, Myxoid

2024-12-20

MCC-19635

P2

Recruiting

Myelodysplastic Syndrome|Preleukemia

2021-05-01

23%

Recent News Events

Date

Type

Title

09/04/2024

News Article

 LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

08/26/2024

News Article

 First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

08/20/2024

News Article

 Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study

08/19/2024

News Article

 LIXTE Biotechnology Provides Update On Recent Activities and Developments

05/10/2024

PubMed

 Enhancing oncogenic signaling to kill cancer cells.

05/01/2024

PubMed

 The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.

03/11/2024

PubMed

 Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions